x € million |
|
Share capital |
|
Share premium |
|
Treasury shares (incl. forward contracts) |
|
Other reserves |
|
Retained earnings |
|
Shareholders’ equity |
|
Non-controlling interests |
|
Total Equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Balance at 1 January 2023 |
|
328 |
|
471 |
|
(196) |
|
363 |
|
9,777 |
|
10,743 |
|
102 |
|
10,845 |
Net profit for the period |
|
– |
|
– |
|
– |
|
– |
|
2,137 |
|
2,137 |
|
16 |
|
2,153 |
Other comprehensive income |
|
– |
|
– |
|
– |
|
116 |
|
(77) |
|
39 |
|
(9) |
|
30 |
Total comprehensive income |
|
– |
|
– |
|
– |
|
116 |
|
2,060 |
|
2,176 |
|
7 |
|
2,183 |
Dividend |
|
– |
|
(425) |
|
– |
|
– |
|
(157) |
|
(582) |
|
– |
|
(582) |
Stock options/share units granted |
|
– |
|
– |
|
– |
|
23 |
|
– |
|
23 |
|
– |
|
23 |
Stock options/share units vested/canceled |
|
– |
|
– |
|
– |
|
(23) |
|
23 |
|
– |
|
– |
|
– |
Reissued shares |
|
– |
|
– |
|
63 |
|
– |
|
(39) |
|
24 |
|
– |
|
24 |
Repurchase of shares |
|
– |
|
– |
|
(256) |
|
– |
|
– |
|
(256) |
|
– |
|
(256) |
Cancellation of shares |
|
(67) |
|
(2) |
|
345 |
|
– |
|
(276) |
|
– |
|
– |
|
– |
Liability to non-tendered shareholders DSM N.V. |
|
(10) |
|
(42) |
|
– |
|
– |
|
(597) |
|
(649) |
|
– |
|
(649) |
Issued new shares (including swap DSM N.V. into DSM-Firmenich AG) |
|
(248) |
|
11,758 |
|
– |
|
– |
|
– |
|
11,510 |
|
– |
|
11,510 |
Expenditures issuance new shares |
|
– |
|
(29) |
|
– |
|
– |
|
– |
|
(29) |
|
– |
|
(29) |
Acquisition of subsidiary with NCI |
|
– |
|
– |
|
– |
|
– |
|
– |
|
– |
|
48 |
|
48 |
Divestment of subsidiary with NCI |
|
– |
|
– |
|
– |
|
– |
|
– |
|
– |
|
(4) |
|
(4) |
Remuneration on deeply subordinated fixed rate resettable perpetual notes |
|
– |
|
– |
|
– |
|
– |
|
(28) |
|
(28) |
|
– |
|
(28) |
Transfer |
|
– |
|
– |
|
– |
|
(5) |
|
(4) |
|
(9) |
|
9 |
|
– |
Other changes |
|
– |
|
– |
|
– |
|
– |
|
(15) |
|
(15) |
|
– |
|
(15) |
Balance at 31 December 2023 |
|
3 |
|
11,731 |
|
(44) |
|
474 |
|
10,744 |
|
22,908 |
|
162 |
|
23,070 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net profit for the period |
|
– |
|
– |
|
– |
|
– |
|
250 |
|
250 |
|
30 |
|
280 |
Other comprehensive income |
|
– |
|
– |
|
– |
|
161 |
|
7 |
|
168 |
|
5 |
|
173 |
Total comprehensive income |
|
– |
|
– |
|
– |
|
161 |
|
257 |
|
418 |
|
35 |
|
453 |
Dividend |
|
– |
|
(414) |
|
– |
|
– |
|
(246) |
|
(660) |
|
(7) |
|
(667) |
Stock options and share units granted |
|
– |
|
– |
|
– |
|
31 |
|
– |
|
31 |
|
– |
|
31 |
Stock options and share units vested/canceled |
|
– |
|
– |
|
– |
|
(26) |
|
26 |
|
– |
|
– |
|
– |
Reissued shares |
|
– |
|
– |
|
54 |
|
– |
|
(33) |
|
21 |
|
– |
|
21 |
Repurchase of shares |
|
– |
|
– |
|
(52) |
|
– |
|
– |
|
(52) |
|
– |
|
(52) |
Forward contracts to repurchase shares |
|
– |
|
– |
|
(105) |
|
– |
|
– |
|
(105) |
|
– |
|
(105) |
Expenditures issuance new shares (in 2023) |
|
– |
|
(4) |
|
– |
|
– |
|
– |
|
(4) |
|
– |
|
(4) |
Acquisition of subsidiary with NCI |
|
– |
|
– |
|
– |
|
– |
|
– |
|
– |
|
– |
|
– |
Divestment/deconsolidation of subsidiary with NCI |
|
– |
|
– |
|
– |
|
– |
|
– |
|
– |
|
(17) |
|
(17) |
Remuneration on deeply subordinated fixed rate resettable perpetual notes |
|
– |
|
– |
|
– |
|
– |
|
(28) |
|
(28) |
|
– |
|
(28) |
Transfer |
|
– |
|
– |
|
– |
|
70 |
|
(89) |
|
(19) |
|
19 |
|
– |
Other changes |
|
– |
|
– |
|
– |
|
– |
|
1 |
|
1 |
|
(6) |
|
(5) |
Balance at 31 December 2024 |
|
3 |
|
11,313 |
|
(147) |
|
710 |
|
10,632 |
|
22,511 |
|
186 |
|
22,697 |
See also Note 16 Equity.